Evidence supporting the use of: Thymic peptides
For the health condition: Acquired Immune Deficiency Syndrome

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Thymic peptides, including thymosin alpha-1 and thymopentin, have been studied as immunomodulatory agents in the context of Acquired Immune Deficiency Syndrome (AIDS). These peptides are derived from the thymus gland and are believed to play a role in T-cell maturation and immune function. Early in the HIV/AIDS epidemic, thymic peptides were explored as potential adjunct therapies due to the profound T-cell depletion seen in affected patients. Several small clinical trials and pilot studies in the 1980s and 1990s evaluated thymic peptides, with some reporting modest improvements in immunological markers (such as CD4+ T cell counts) and, in rare cases, clinical symptoms. However, these studies often suffered from methodological limitations such as small sample sizes, short follow-up periods, and lack of robust controls. Subsequent larger and more rigorous trials failed to demonstrate consistent or meaningful clinical benefit in HIV-positive individuals, particularly with the advent of highly active antiretroviral therapy (HAART), which dramatically improved patient outcomes. Current clinical guidelines do not recommend thymic peptides for the treatment of AIDS, and their use is not supported by strong scientific evidence. Therefore, while there is some scientific rationale and limited clinical investigation, the overall quality and consistency of the evidence is low, leading to a rating of 2 out of 5.

More about Thymic peptides
More about Acquired Immune Deficiency Syndrome

Products containing Thymic peptides

We currently have no products on Vitabase that contain this ingredient.